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Abstract The normal gastrointestinal stroma consists of
extra-cellular matrix and a community of stromal cells
including fibroblasts, myofibroblasts, smooth muscle cells,
pericytes, endothelium and inflammatory cells. α-smooth
muscle actin (α-SMA) positive stromal fibroblasts, often
referred to as myofibroblasts or activated fibroblasts, are
critical in the development of digestive cancer and help to
create an environment that is permissive of tumor growth,
angiogenesis and invasion. This review focusses on the
contribution of activated fibroblasts in carcinogenesis and
where possible directly applies this to, and draws on
examples from, gastrointestinal cancer. In particular, the
review expands on the definition, types and origins of
activated fibroblasts. It examines the molecular biology of
stromal fibroblasts and their contribution to the peritumoral
microenvironment and concludes by exploring some of the
potential clinical applications of this exciting branch of
cancer research. Understanding the origin and biology of
activated fibroblasts will help in the development of an
integrated epithelial-stromal sequence to cancer that will
ultimately inform cancer pathogenesis, natural history and
future therapeutics.
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Introduction
Digestive cancers cause a staggering global health burden [1].
In the US in 2008 it was estimated that more than 270,000
patients were diagnosed with and more than 135,000 died
from cancers of the digestive system [2]. Carcinogenesis
research has largely focused on the stepwise accumulation of
molecular events within epithelial cells, but it is now clear
that the peritumoural stroma is also critical in the initiation
and progression of gastrointestinal cancer [3–9].
The normal gastrointestinal stroma consists of a struc-
tural and functional scaffolding known as the extra-cellular
matrix (ECM) that supports an integrated community of
stromal cells, including fibroblasts, myofibroblasts, smooth
muscle cells, pericytes, endothelium and a variable popu-
lation of inflammatory cells [8]. In addition, a specialized
matrix known as the basement membrane separates the
epithelium from the underlying stroma [10, 11]. The
predominant structural protein in the ECM is collagen,
with type IV collagen the chief component of the basement
membrane [9]. Other important ECM and basement
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Stromal cells communicate through direct cellular con-
nections, paracrine mediators and cellular-ECM interactions
[3]. Together, the basement membrane and the ECM are
important in maintaining normal epithelial function and
retarding carcinogenesis [9], as well as regulating stromal
cell motility and migration [7, 12, 13]. In cancer, matrix
metalloproteinases are important in ECM and basement
membrane-remodelling and can promote carcinogenesis [9].
Invasive carcinoma is defined by the interruption of
normal cellular compartments [3, 4, 14, 15]. The invasion
field between pre-existing epithelial and stromal compart-
ments is a critical interface in carcinogenesis and leads to the
important question of which compartment leads in this danse
macabre [5]. Ultimately, however, one should address all
aspects of cancer’s heterotypic cellular biology, including
malignancy, mesenchyme and matrix [14, 16–18].
This review focusses on the contribution of stromal
fibroblasts to cancer and where possible directly applies this
to, and draws on examples from, gastrointestinal carcino-
genesis. In particular the review expands on the definition,
types and origins of stromal fibroblasts. It examines their
molecular biology and contribution to the peritumoral
microenvironment and concludes by exploring some of
the potential clinical applications of this exciting branch of
cancer research.
The analogy of epithelium and stroma sharing a
neoplastic “seed and soil” relationship was first docu-
mented 120 years ago [19]. Whilst, much of the molecular
revolution has focussed on the epithelial “seed”, there has
been burgeoning interest in dissecting out the stromal
factors that serve to initiate, support and progress carcino-
genesis. Furthermore, it is likely that the stroma is more
than simply a permissive accomplice, as suggested by the
analogy, but rather will prove to be an active partner in
carcinogenesis [20].
Stromal Cells in Digestive Cancers
More than half the mass of digestive cancers is usually
accounted for by the cancer stroma [6]. Whilst gastroin-
testinal cancer stroma varies with cancer site and biology,
as demonstrated by the specific lymphocytic stromal
infiltrate found in hereditary non-polyposis colorectal
cancer [21], many stromal events are common across
different digestive cancers, solid organ cancers more
generally and even some hematological malignancies [3].
In this section the main stromal cell types will be defined
and discussed with special attention given to stromal
fibroblasts and myofibroblasts.
Fibroblasts and Myofibroblasts
Fibroblasts and myofibroblasts are important cells within
the tumor stroma. On light microscopy, fibroblasts appear
as spindle shaped cells surrounded by ECM. In normal
gastrointestinal stroma, fibroblasts are usually quiescent
and are characterized by the expression of both vimentin
and desmin. In their inactive state, fibroblasts do not
express α-smooth muscle actin (α-SMA) but can be
stimulated to express α-SMA under the influence of the
reactive stroma [7, 8, 22]. Activated fibroblasts have large
euchromatic nuclei, a prominent nucleoli and, on electron
microscopy (EM), prominent rough endoplasmic reticulum
(rER) and Golgi apparatus [14, 22]. In cancer research, α-
SMA(+) stromal fibroblasts are often referred to as
myofibroblasts [7, 8, 14, 22–24]. Some investigators
caution against this approach because it tends to label
several different cell types “myofibroblasts” despite vari-
able ultrastructural features on EM [22, 25].
Some recommend that the term “myofibroblast” be
reserved for cells that satisfy strict criteria:
1. typical appearing, spindle-cell
2. within typical pericellular matrix
3. positive for: α-SMA, vimentin, non-muscle myosin and
EDA cellular fibronectin.
4. ultrastructural confirmation by EM, demonstrating:
prominent rER and Golgi apparatus, myofilaments with
focal densities, gap junctions, fibronexuses consisting of
converging filaments and external fibronectin fibril [22].
Others endorse a more liberal classification of myofi-
broblasts, defined by their light microscopic appearance
and relative expression of vimentin, desmin and α-SMA:
1. V myofibroblasts (vimentin(+) only)
2. VM myofibroblasts (vimentin and myosin(+))
3. VA myofibroblasts (vimentin and α-SMA(+))
4. VAD myofibroblasts (vimentin, α-SMA and desmin
(+)) [7]
The clinicopathological correlates of this specific immu-
nohistochemical categorization, however, are uncertain.
Given that α-SMA is the best immunohistochemical maker
of myofibroblasts [26], some advocate classifying only the
VA and VAD subtypes as true myofibroblasts [8].
Given the reliance on light microscopy and the utility of
immunohistochemistry in cancer research, a reasonable
approach is to acknowledge that there is a community of
“α-SMA(+) fibroblast-like cells”, which includes both
“physiological cells” as well as “reactive cells”. “Physio-
logical” α-SMA(+) fibroblast-like cells are evident within
the normal tissue stroma but “reactive” α-SMA(+)
fibroblast-like cells are only present within the “reactive”
stroma in the setting of tissue injury or disease. α-SMA(+)
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hepatic stellate cells, pericytes and intestinal subepithelial
myofibroblasts (ISEMFs). The α-SMA(+) fibroblast-like
“reactive cells” include the activated stromal fibroblasts seen
in benign wound healing as well as the cancer-associated
fibroblasts (CAFs) found in the peritumoral stroma [6].
Whilst, all “α-SMA(+) fibroblast-like cells” do not conform
to the original EM-description of “the myofibroblast” [27–
29], many of the CAFs do indeed share the ultrastructural
features of fully differentiated myofibroblasts [22].
Using the term “myofibroblast” for typical appearing α-
SMA(+) cells within the peritumoural stroma, provided
they are not peri-endothelial pericytes, is widely endorsed
[5–7, 9, 11, 14, 23, 26]. Better still, perhaps, is reserving
the term “myofibroblast” for α-SMA(+) stromal fibroblasts
that also have phenotypically consistent expression across
additional markers, such as vimentin and prolyl 4-
hydroxylase (+) and cytokeratin (−) or that are confirmed
on EM [30]. In this review, unless satisfying the preceding
criteria, fibroblast-like cells within the reactive stroma will
be referred to by the less demanding, and less precise [31],
term CAF if it is peritumoral or “α-SMA(+) or (−) stromal
fibroblast” if it resides within benign tissue [30]. Unfortu-
nately, such an approach still presents some difficulties.
Chronic inflammation often precedes the development of
invasive digestive carcinomas. Thus, the same α-SMA(+)
stromal fibroblasts present in the reactive stroma immedi-
ately before invasion would be renamed CAFs immediately
following invasion, although their structure and function
may be unchanged. This issue is particularly important in
animal cancer models, such as gastric carcinoma, that have
well established, progressive premalignant epithelial pa-
thology [32]. Another difficulty is that CAFs are biologi-
cally heterogeneous and may not be adequately categorized
by the expression of α-SMA alone [31, 33]. Ultimately,
more sophisticated gene expression and epigenetic profiling of
thesecellsmayresolvesomeoftheseuncertainties,particularly
ifspecificmolecularsignaturescanbefoundthatareassociated
with key outcomes in terms of chronic inflammation and
healing [34, 35], or carcinogenesis, metastasis and prognosis
[36–38]. Although a combined EM and immunohistochem-
istry approach is currently the ideal [25], researchers will
continue to balance available resources against the benefits of
phenotypic and semantic precision.
Other Important Stromal Cells
Inflammatory Cells
Inflammatory cells help to define the reactive stroma [32,
39]. In the reactive stroma that accompanies Helicobacter
pylori infection and gastritis, there is a vigorous cytokine
response [40, 41]. Firstly, neutrophils are recruited to the
stroma byIL-8 and then additional chemokines attract chronic
inflammatory cells, such as lymphocytes, monocytes and
plasma cells [32, 40, 41]. Macrophages differentiate from
circulating monocytes under the influence of IL-6 and
leukemia inhibitory factor and help to coordinate the inflam-
matory response [8]. Inflammatory cells are readily discrim-
inated from fibroblasts in the stroma by morphology as well
as their expression of the panhematopoietic marker CD45.
Pericytes and Endothelial Cells
Neovascularization involves the recruitment and prolifera-
tion of pericytes and endothelium and is critical in
carcinogenesis. Pericytes are usually crescentic, mesenchy-
mal cells, intimately associated with normal endothelium in
the microcirculation [14]. Pericytes usually co-express α-
SMA and desmin [22], and thus may occasionally be
confused with myofibroblasts particularly in the setting of
the disordered vasculature that accompanies carcinogenesis.
Pericytes are important in regulating endothelial permeability
and blood flow. Their exact origin is uncertain, but they may
arise from local smooth muscle cells or myofibroblasts or
alternatively may develop from bone-marrow derived cells
(BMDCs), such as multipotent mesenchymal stromal cells
(MSCs) [8]. Endothelial cells, of course, are extremely
important in health and disease, particularly cancer. Endo-
thelial cells are characterized by co-expression of CD31, von
Willebrand factor and CD34 [22]. In cancer, the endothelium
originates in part from circulating bone-marrow derived
endothelial progenitor cells [42].
Smooth Muscle Cells
Stromal smooth muscle cells occur within the parenchyma
as well as within the walls of arteries and arterioles.
Parenchymal smooth muscle cells have far less intercellular
matrix surrounding them than is found in the context of
fibroblasts and myofibroblasts within the ECM. Neverthe-
less, the expression of α-SMA in both smooth muscle and
myofibroblasts may occasionally cause some difficulties in
distinguishing these two cells. Smooth muscle cells, however,
can be defined by their co-expression of smoothelin and
caldesmon [6].
Other Important Physiological Gastrointestinal α-SMA(+)
Cells
Intestinal Subepithelial Myofibroblasts (ISEMFs)
Intestinal subepithelial myofibroblasts, also known as
pericryptal fibroblasts, are α-SMA(+) mesenchymal cells
that occur throughout the alimentary tract (Fig. 1). They
reside immediately beneath the epithelial basement mem-
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smooth muscle heavy chain myosin, vimentin, the fibroblast
markers prolyl 4-hydroxylase and CD90, but not the smooth
muscle markers smoothelin or desmin [6]. Furthermore, the
smooth muscle marker h-caldesmon has also been identi-
fied in some pericryptal cells [22]. These cells interconnect
with the other key mesenchymal elements throughout the
intestinal lamina propria, including fibroblasts, pericytes
and the muscularis mucosae [6]. Electron microscopy
suggests that these cells share many of the typical features
of myofibroblasts including microfilament bundles, dense
bodies and a well developed rER and Golgi apparatus [6].
Typical myofibroblasts, however, tend to have slightly
more rER and do not express caldesmon [22].
The putative intestinal “stemcellniche” may bedefined by
ISEMFs in collaboration with other local cells as well as the
basement membrane [6, 7]. The ISEMFs are believed to help
create a specialized, discrete microenvironment to nurture,
maintain and regulate tissue specific stem cells, to promote
their quiescence and capacity for long-term self renewal [43].
In addition, neurons contribute to the melanocyte stem cell
niche [44] and have previously been shown to be important
within the bone marrow niche [45]. The nervous system
might also be important within the development and
maintenance of any digestive “stem cell niche”.
Intestinal subepithelial myofibroblasts produce regionally-
specific growth factors, possibly contributing to the regional
epithelial differences along the alimentary tract and are
capable of organizing endoderm into well differentiated villi,
containing enterocytes, goblet cells and enteroendocrine cells
[6]. Their intestinal differentiating capacity is also evident
from studies in which ISEMFs were co-cultured with colon
cancer cell lines [46]. T84 cell line colonies, co-cultured with
the ISEMFs, organized into basement membrane limited
luminal structures and almost half of the colonies developed
into single-layer columnar epithelium with intestinal micro-
villi, alkaline phosphatase, brush border activity and mucin
[46]. The discovery of an intestinal stem cell marker, Lgr5,
promised to clarify the nature of the intestinal stem cell niche
[47]. Interestingly, however, Lgr5+ intestinal stem cells were
recently shown to be capable of semi-autonomous organiza-
tion into crypt-villus structures, without the need for any
discrete cellular mesenchymal niche [48]. In this experiment,
however, the supportive environment contained several
mesenchymal factors such as EGF and R-spondin 1 [48].
Thus, the precise in vivo role of ISEMFs as possible
“niche cells”, awaits further research. The exciting
corollary of ISEMFs as physiological niche cells is the
possible role of some CAFs as pathological niche cells in
the setting of digestive cancer stem cells [49]. Further-
more, re-establishing a physiological “niche” might be a
possible strategy to restore normal epithelial biology.
Interstitial Cells of Cajal (ICCs)
ICCs are α-SMA(+) cells exhibiting typical myofibroblast
morphology on light microscopy [23]. On EM, however,
these cells appear more like modified smooth muscle cells
than typical myofibroblasts [22]. These cells are often found
in the intermuscular space between the circular and longitu-
dinal layers of the muscularis propria of the stomach, small
intestine and colorectum [23]. ICCs function as pacemaker
cells to coordinate smooth muscle motility, facilitate electrical
signaling and regulate neurotransmission [23]. ICC dysfunc-
tion is implicated in Hirschprung’s disease and achalasia and
ICCs are the cellular origin of gastrointestinal stromal tumors,
the most common abdominal mesenchymal tumor [50].
The Development and Derivation of CAFs
and Myofibroblasts
Gastrointestinalmesenchymalelements begin their development
with the encircling of the endoderm by the lateral plate
Fig. 1 a Gastric cancer and b
rectal adenoma in two female
patients following male human
allogeneic haematopoietic stem
cell transplantation. Using Y-
chr. CISH and α-SMA immu-
nohistochemistry bone marrow
derived α-SMA(+) gastric CAFs
in A and ISEMFs in B (black
arrows, reproduced with
permission) [53]
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and mesoderm undergo extensive and integrated development
along five different axes: the cranial-caudal, left-right, anterior-
posterior, radial and the crypt-villus axes [51]. It is likely that
neither the mesoderm nor the endoderm holds all of the
information required for gastrointestinal embryogenesis with
intimate signaling between these two germ layers being
necessary for normal development. It is uncertain whether
ISEMFs develop from the mesoderm or the neural crest, but
they are evident within the mesenchymal layer by 21 weeks
gestation [51]. In mice, ISEMFs have been described from
E18.5 (18.5 days post coitum) [51]. ISEMFs are very important
in the embryogenesis of the functional epithelial axis through-
out the alimentary tract, such as the crypt-villus axis in the
small intestine. Hedgehog, Wnt and BMP pathway signaling
between the epithelium and the mesoderm, probably via
ISEMFs, is critical for normal crypt-villus development [51].
Post-embryogenesis, several animal and human alloge-
neic stem cell transplantation studies have shown that
mesenchymal elements such as ISEMFs and CAFs are
derived, at least in part, from BMDCs, possibly MSCs
(Figs. 1 and 2)[ 52–59]. Other studies, however, suggest
that local tissue compartments may harbor cells capable of
developing into CAFs (Fig. 2)[ 14, 17, 18].
CAFs and Myofibroblasts in Cancer
Normal stroma contains very few fibroblasts, but there is a
dramatic increase in fibroblast-like cells within the reactive
stroma surrounding inflamed or neoplastic tissue [14]. In
normal wound healing there is an initial aggregation and
activation of platelets, enhanced vascular permeability and
an influx of fibrinogen to promote hemostasis. Platelets
release a number of regulatory factors including transforming
growth factor-β (TGF-β) and platelet-derived growth factor
(PDGF) leading to an expansion of α-SMA(+) fibroblasts
and other cells, which in turn produce growth factors, such
as vascular-endothelial growth factor (VEGF) and fibroblast
growth factor-2 (FGF2)(Fig. 2). α-SMA(+) stromal fibro-
blasts also produce a number of important proteolytic
enzymes, which help to generate granulation tissue and
achieve re-epithelialization. There are many parallels be-
tween normal wound healing and the cancer stroma [4, 59].
In inflammatory digestive cancers, such as gastric cancer,
the reactive stroma precedes dysplasia and cancer [24].
Similarly, in colorectal adenomas there is already a signif-
icant expansion of the ISEMF population compared to
normal colorectal mucosa [60, 61]. Thissuggeststhatstromal
fibroblasts may play a role in propagating pre-malignant
lesions as well as in promoting advanced events such as
invasion and metastasis. This notion of an early contribution
of stromal fibroblasts to cancer was supported by an elegant
study investigating the FSP1-Cre TGFβIIR
flox/flox mouse, a
model in which all fibroblasts lack the TGFβ type II
receptor [10, 62]. These mice developed increased rates of
forestomach squamous cell carcinoma and prostate neo-
plasia [62]. This suggested that an underlying abnormality
of the fibroblast could initiate as well as advance epithelial
cancer [10, 62].
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Fig. 2 Schematic representation
of the gastrointestinal stroma:
the key stromal cells and events
within the reactive stroma
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important inflammatory mediators, including matrix-
metalloproteinases -2, -3 and -9, which can alter the
stromal ECM and potentiate invasion, cell motility and
metastasis [14, 63–66]. Cancer-associated fibroblasts also
produce stromal derived factor-1 (SDF-1), VEGF, hepato-
cyte growth factor (HGF), insulin-like growth factor
(IGF), nerve growth factor, WNT1, epidermal growth
factor (EGF) and FGF2, which can directly promote
growth in the adjacent epithelium and neovascularization
within the stroma (Fig. 2)[ 14]. Stromal fibroblasts may
also be important in promoting the seeding and sustenance
of distant micrometastasis, possibly mediated through
their promotion of local invasion and angiogenesis [14].
A critical issue is whether stromal fibroblasts are normal
cells in abnormal circumstances or whether they are
different from their normal tissue counterparts. The weight
of evidence suggests that CAFs are indeed different to the
normal cells [14, 67, 68]. In one study, breast CAFs were
more likely than normal fibroblasts to enhance tumor
growth, to express α-SMA(+), to produce SDF-1, to
enhance angiogenesis and to stimulate the CXCR4 receptor
[67, 68]. Local SDF-1 production by these cells was also
shown to enhance the chemotaxis of CXCR4-expressing
endothelial progenitor cells (EPCs) and hematopoietic pro-
genitor cells (HPCs), into the stroma [68]. CXCR4 is also
expressed by a small proportion of MSCs [69], which may
be relevant in the recruitment of these cells into the stroma to
develop into bone marrow derived CAFs. Cancer-associated
fibroblasts from prostate cancer are also significantly
different, showing greater tumor potentiating effects in vitro
and in vivo compared to normal prostatic fibroblasts [70].
The increase in α-SMA(+) stromal fibroblasts within the
reactive stroma may occur through a combination of
different mechanisms. Firstly, chemokines such as SDF-1
may recruit fibroblast precursors, possibly MSCs or HPCs,
into the stroma from the bone marrow. In the context of
additional factors, including PDGF and TGF-β,t h e s e
precursors may differentiate into α-SMA(+) stromal fibro-
blasts (Fig. 2). In culture, TGF-β can activate normal
fibroblasts into α-SMA(+) fibroblasts [71]. Secondly, TGF-
β and PDGF may act on resident inactive fibroblasts to
induce myofibroblastic differentiation [72]. Finally,
epithelial-mesenchymal transition (EMT), possibly also
promoted by PDGF and TGF-β, could explain some of
the stromal fibroblasts [14, 17, 18].
It is likely that CAFs are biologically heterogeneous and
that this heterogeneity extends beyond merely whether they
do, or do not, express α-SMA [31, 33]. One study recently
characterized stromal fibroblasts from two mouse models of
cancer [33]. They identified a distinct subpopulation of
FSP-1(+) CAFs that did not seem to significantly express
other “typical” stromal fibroblast markers, such as α-SMA,
vimentin, fibroblast-activation protein, fibroblast-associated
antigen or prolyl 4-hydroxylase [33]. This study suggested a
biological dichotomy within stromal fibroblasts. This could
reflect the activity of the cells studied, activated versus non-
activated, or perhaps even the origin of the cells, local as
opposed to bone marrow derived. New markers and new
techniques may be needed to understand the heterogeneous
biology and thus diverse stromal consequences of CAFs.
Gastric cancer is one of the key digestive cancer models
that has explored the origin and the role of CAFs [8, 24, 32,
39, 53, 54, 58, 73, 74]. From studies using the Helicobacter
felis C57BL/6 model of gastric cancer, it is clear that bone-
marrow derived α-SMA(+) fibroblasts enter the pre-
malignant chronically inflamed reactive gastric stroma
[54]. Bone marrow derived CAFs have also been confirmed
in human gastric cancer (Fig. 1a)[ 53]. As discussed above,
these cells are likely to play an important role in the
progression and potentially even in the initiation of gastric
carcinogenesis [10, 62].
Are CAFs Molecularly Transformed?
Excluding rare examples of primary myofibroblastic ma-
lignancies [75], CAF precursors presumably begin as
normal cells [68]. A possible caveat, outlined above, would
be if CAFs developed via EMT from neoplastic epithelium.
In this scenario, one would expect to find common genetic
abnormalities in epithelium and stroma. Once activated,
however, CAFs seem to maintain their activated phenotype
even when removed from the activated stroma [68]. This
led researchers to consider whether these cells had
undergone any genetic alterations that would sustain their
autonomous activity. The results have been somewhat
mixed [68]. In 2002, an exciting report emerged that
mutations and loss of heterozygosity at TP53 and PTEN
could be detected in breast cancer stroma [76, 77]. Although
the genetic aberrations in cancer and stroma were usually
discordant, there were 2 cases of identical mutations in TP53
[77]. This report was followed by a series of informative
studies conducted in patients with inherited as well as
sporadic breast cancer [78–80]. In all studies they confirmed
the presence of significant stromal genetic instability [78–
80]. Furthermore, in one study they found that stromal LOH
was closely correlated with important clinicopathological
characteristics, including tumor grade and stage [80].
These findings of stromal genetic instability were
supported by a second group studying ovarian cancer [81,
82]. These studies initially analyzed 6 microsatellites on
chromosome 3p [82], and then confirmed the genetic
instability in a larger study at 110 loci [81]. Interestingly,
they described a number of genetic events that were
common to cancer and stroma, raising the possibility of
122 D.L. Worthley et al.EMT [81, 82]. The presence of stromal genetic instability
has also been described in colitis-associated colorectal
cancer and in a mouse model of prostate cancer [83, 84].
Not all studies, however, have identified significant
genetic alterations in the stroma [68, 85, 86]. One recent
study analyzed 25 ovarian and 10 breast cancer specimens
using a 500K SNP array platform [86]. Only one patient
was identified with LOH in the stromal compartment [86].
Reconciling these discrepant results is difficult owing to
the inherent differences in the types of tissues analyzed,
fresh frozen vs. archival formalin fixed specimens, the
different techniques used and the exact compartments, and
thus cells, analyzed [86].
Thereisgreater consensus insupportofepigeneticchanges
in CAFs [74, 87, 88]. One study analyzed promoter region
methylation in the stroma of five patients with prostate
cancer [87]. Aberrant stromal methylation was reported in
four patients, but it was unclear whether these changes were
truly stroma-specific [87]. The other studies were more
persuasive and adopted a genome-wide approach to DNA
methylation [74, 88] .T h ef i r s t ,u s e dm e t h y l a t i o n - s p e c i f i c
digital karyotyping to analyze DNA methylation in breast
cancer cells, associated myoepithelial cells and stromal
fibroblasts [88]. Distinct epigenetic changes were found for
each cell type [88]. The second study, more interesting from
a digestive cancer perspective, used methylation-sensitive
SNP arrays to analyze DNA methylation in gastric CAFs
[74]. The gastric CAFs had widespread DNA hypomethyla-
tion, which was confirmed by loss of 5-methylcytosine
staining on immunohistochemistry [74]. DNA hypomethy-
lation is a frequent event in cancer [89]. DNA hypomethy-
lation of repetitive genomic sequences in cancer is associated
with genetic instability [89]. It is possible that DNA
hypomethylation in CAFs also promotes genetic instability.
These studies suggest that genetic abnormalities can
occur within the stroma [20], although the frequency is
uncertain and it may be relatively uncommon [86, 90]. It is
likely, however, that CAFs have an altered epigenetic
profile, which may help to explain their unique biology
[90]. Future studies should focus on cell specific rather than
compartmental analysis to help resolve some of the
discrepancies and better characterize the evolution and
biology of these important cells.
Clinical Potential of Stromal Fibroblast Research
in Digestive Cancer
There are several exciting potential clinical implications of
stromal fibroblast research for the prevention, diagnosis and
management of digestive cancer. The accessibility of the
digestive tract to endoscopic sampling provides the oppor-
tunity of integrating stromal fibroblast analysisinto digestive
cancer surveillance for conditions such as Barrett’s esopha-
gus or chronic ulcerative colitis. For patients with cancer,
new agents could be developed to antagonize the CAF-
related promotion of tissue invasion and metastasis. To some
extent this has already been realized with the development of
bevacizumab, which is an anti-VEGF monoclonal antibody
used in the treatment of several solid organ cancers,
including colorectal cancer. Furthermore, the tumor stroma
could be manipulated to improve the delivery of chemother-
apy. An inhibitor of hedgehog signaling was recently used in
an animal model of pancreatic cancer. The agent inhibited
peritumoral stromal desmoplasia and as a result improved
drug delivery to the tumor [91]. Finally, given that CAFs
can originate from the bone marrow, a therapeutically
manipulable compartment, CAF-related research could
theoretically prefigure attempts to use stem cell transplan-
tation as a means of indirectly seeding and thus modifying
the cancer microenvironment.
Summary
Stromalfibroblasts are criticalinthe development ofdigestive
cancer. The reactive, peritumoral stroma shares many charac-
teristics with the reactive stroma associated with “normal”
wound healing [4]. Expression of α-SMA in stromal
fibroblasts is a good marker of myofibroblastic differentia-
tion, but may not adequately categorize the full biological
heterogeneity of CAFs. In the future, expression profiling or
other means of genetic and epigenetic analysis may help to
better characterize these cells into coherent subtypes. In turn,
improved characterization may facilitate a better appreciation
of the dynamic changes that occur within the stroma.
Understanding the origin and biology of stromal fibroblasts
will help in the development of an integrated epithelial-
stromal sequence in digestive cancers and will ultimately
inform pathogenesis, natural history and future therapeutics.
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